Overall Score

Threat Of New Entrants

Biotech development still requires substantial R&D, regulatory approval, and commercialization expertise, which raises barriers to entry.

BCRX’s current liquidity profile remains solid with a current ratio of 2.32, supporting ongoing development and launch execution.

Bargaining Power Of Suppliers

The company’s manufacturing and development inputs are specialized, but no new supplier concentration issue is evident this month.

Low capex intensity and strong operating cash flow coverage suggest limited near-term dependence on external supplier financing.

Bargaining Power Of Buyers

Buyers in rare-disease and specialty biotech markets typically have limited alternatives, which supports pricing power.

However, BCRX’s negative net margin and ongoing losses indicate it still needs commercial traction to sustain leverage over payers and providers.

Threat Of Substitutes

Therapeutic substitutes remain a meaningful constraint in biotech, especially where competing treatments or standard-of-care options exist.

BCRX’s gross margin of 23.5% suggests it has room to defend economics, but not enough to imply insulation from substitution risk.

Rivalry Among Existing Competitors

Competition remains elevated in biotech because rivals can target the same indications with differentiated mechanisms or better clinical data.

BCRX’s valuation at 2.93x EV/Sales and negative EBITDA margin indicate the market still prices in meaningful execution and competitive pressure.